I was asked if there was one item that was a real game changer at the American Society of Clinical Oncologists (ASCO) meeting for men with advanced prostate cancer. The answer is yes, at this meeting it was formally shown by a study that starting chemotherapy (docetaxel) along with androgen deprivation therapy (ADT) in some [...]
I have been at American Association of Clinical Oncologists (ASCO) since last Thursday. On the prostate cancer front the most exciting part of the meeting has been our being in Chicago and that the weather which has been fantastic. The only truly newsworthy thing that I have come across so far has been an abstract [...]
As usual, we are confronted with a new contradiction. It has been believed that earl hormone therapy (ADT) in men with a biochemical recurrence (PSA only) would benefit from immediate ADT. A study released from the Harvard School of Public Health contradicts this assumption, but the study lacks follow up beyond 10 years. They evaluated [...]
Androgen deprivation therapy (ADT) is the most common first therapy for men diagnosed with metastatic prostate cancer as well as many men with non-metastatic prostate cancer. ADT brings with it many side effects including significant weight gain. Weight gain, which may contribute to cardiovascular comorbidities as well as diabetes, is among the many adverse metabolic [...]
